A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease

BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of Crohn’s disease and may serve as a potential biomarker. A phase 2 trial was conducted to examine the efficacy and safety of the anti-MMP9 antibody andecaliximab [GS-5745] in patients with moderately to severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Stefan, Siegel, Corey A, Friedenberg, Keith A, Younes, Ziad H, Seidler, Ursula, Bhandari, Bal R, Wang, Ke, Wendt, Emily, McKevitt, Matt, Zhao, Sally, Sundy, John S, Lee, Scott D, Loftus, Edward V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113705/
https://www.ncbi.nlm.nih.gov/pubmed/29846530
http://dx.doi.org/10.1093/ecco-jcc/jjy070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113705/
https://www.ncbi.nlm.nih.gov/pubmed/29846530
http://dx.doi.org/10.1093/ecco-jcc/jjy070

Ejemplares similares